Compare Booz Allen Hamilton Holding Corporation (BAH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Neurocrine Biosciences Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $77.99 (market cap $9.45B), while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BAH | NBIX | |
|---|---|---|
Market Cap | $9.45B | $16.46B |
Sector | Industrials | Health |
52-Week High | $111.63 | $185.50 |
52-Week Low | $59.71 | $123.10 |
Enterprise Value | $13.07B | $16.48B |
Dividend Yield | 3% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
